Press releases
- Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
- Rigel to Present at the Jefferies Global Healthcare Conference
- Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
- Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
- Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
More ▼
Key statistics
As of last trade, Rigel Pharmaceuticals Inc (RI2A:FRA) traded at 0.8665, 29.64% above the 52 week low of 0.6684 set on Oct 26, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8665 |
---|---|
High | 0.8665 |
Low | 0.8665 |
Bid | 0.8555 |
Offer | 0.9075 |
Previous close | 0.8765 |
Average volume | 108.89 |
---|---|
Shares outstanding | 175.41m |
Free float | 171.71m |
P/E (TTM) | -- |
Market cap | 171.51m USD |
EPS (TTM) | -0.1135 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:42 BST.
More ▼